FierceBiotech Names C4 Therapeutics as One of Its “Fierce 15” Biotech Companies of 2016

“We are humbled to be named a 2016 Fierce 15 company,” said Andrew Phillips, Ph.D., President and Chief Scientific Officer of C4 Therapeutics. “Since launching the company in January this year, the C4T team has rapidly built a world-class science organization, made tremendous headway on internal projects, and moved forward with our partner Roche. The Fierce15 award is a testament to this momentum, and also to the potential of our approach to targeted protein degradation for developing transformative new therapeutics.”

The Fierce 15 celebrates the spirit of being “fierce” – championing innovation and creativity, even in the face of intense competition. This is FierceBiotech’s fourteenth annual Fierce 15 selection.

An internationally recognized daily report reaching a network of over 300,000 biotech and pharma industry professionals, FierceBiotechprovides subscribers with an authoritative analysis of the day’s top stories. Every year FierceBiotech evaluates hundreds of private companies from around the world for its annual Fierce 15 list, which is based on a variety of factors such as the strength of its technology, partnerships, venture backers and a competitive market position.

About FierceBiotech

FierceBiotech is the biotech industry’s daily monitor, an email newsletter and web resource providing the latest biotech news, articles, and resources related to clinical trials, drug discovery, FDA approval, FDA regulation, patent news, pharma news, biotech company news and more. More than 160,000 top biotech professionals rely on FierceBiotech for an insider briefing on the day’s top stories. Signup is free at

About C4 Therapeutics

C4 Therapeutics is a private biotechnology company developing a new class of drugs based on Targeted Protein Degradation (TPD) to address a broad range of life-threatening and life-impairing diseases. C4T’s Degronimid™ platform uses small molecule drugs to direct the machinery of the ubiquitin-proteasome system to selectively degrade disease-relevant proteins for therapeutic benefit. Leveraging this distinctive mechanism provides new opportunities to target traditionally difficult to treat diseases and drug resistance. The wide-ranging potential of the Degronimid approach underpins C4T’s internal drug discovery programs as well as strategic partnerships with leading global pharmaceutical and biotechnology firms.

More information about C4 Therapeutics is available at


Rebecca Willumson, 202-824-5050
[email protected]
MacDougall Biomedical Communications
Kari Watson or Casey R. Doucette, Ph.D.

[email protected] or [email protected]